<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367820</url>
  </required_header>
  <id_info>
    <org_study_id>14-181-08</org_study_id>
    <nct_id>NCT02367820</nct_id>
  </id_info>
  <brief_title>Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain</brief_title>
  <acronym>SUMMIT-LTS</acronym>
  <official_title>A Phase 3 Multicenter, Open-Label, 52-Week Study To Evaluate the Long-Term Safety and Tolerability of NKTR-181 in Subjects With Moderate to Severe Chronic Low Back Pain or Chronic Non-Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nektar Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this 52-week open label study is to determine the long-term safety of a new&#xD;
      opioid molecule, NKTR-181, in patients with moderate to severe chronic low back pain or&#xD;
      chronic non-cancer pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label safety and tolerability study in which approximately 600 subjects will&#xD;
      receive NKTR-181 for up to 52 weeks. Subjects may include newly enrolled subjects and&#xD;
      subjects who have recently completed SUMMIT-07 study.&#xD;
&#xD;
      This study will also investigate the pharmacokinetics of NKTR-181 in patients with chronic&#xD;
      low back pain or chronic non-cancer pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Events</measure>
    <time_frame>Screening baseline through end of study, an average of 57 weeks</time_frame>
    <description>Count of subjects reporting treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory (BPI) Pain Intensity Item to Week 52</measure>
    <time_frame>Baseline, monthly change from baseline till the end of study</time_frame>
    <description>A self-reported scale measuring severity of pain on function. The mean of the 4 intensity items (3-6) is calculated and used as a measure of pain severity. If there were missing items when the pain severity score was calculated, the mean of the completed items in one dimension (dimensions include pain severity and pain interference) were imputed to substitute the missing item, provided that more than 50% of the items in one dimension were completed (Halling, 1999). The range of pain intensity and interference for each question is from 0 to 10. The range of possible scores is from 0 to 70. Higher score indicates relatively worse pain severity and greater interference that pain causes in day to day activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory (BPI) Pain Interference Item to Week 52</measure>
    <time_frame>Baseline, monthly change from baseline till the end of study</time_frame>
    <description>A self-reported scale measuring interference of pain on function. The mean of the 7 interference items was calculated and used as a measure of Pain interference. If there were missing items when the pain interference score was calculated, the mean of the completed items in one dimension (dimensions include pain severity and pain interference) were imputed to substitute the missing item, provided that more than 50% of the items in one dimension were completed (Halling, 1999). The range of pain interference is from 0 to 10. Higher score indicates relatively worse pain problem.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">638</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>NKTR-181</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NKTR-181 twice daily (BID) tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-181 BID tablets</intervention_name>
    <description>NKTR-181 tablets 100-600 mg twice daily (BID)</description>
    <arm_group_label>NKTR-181</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-nursing female aged 18 to 75 years old&#xD;
&#xD;
          -  Clinical diagnosis of moderate to severe, chronic low back or non-cancer pain for at&#xD;
             least three months&#xD;
&#xD;
          -  Not experiencing adequate pain relief or have failed previous treatment with&#xD;
             non-opioid analgesics&#xD;
&#xD;
          -  Opioid analgesia is necessary&#xD;
&#xD;
          -  Currently taking no less than 10 mg but no more than 60 mg of morphine sulfate&#xD;
             equivalents (MSE) per day of opioid analgesics for at least 7 days prior to entry&#xD;
&#xD;
          -  Females of child bearing potential must be using a highly effective form of birth&#xD;
             control. All subjects must agree to use double-barrier contraception during&#xD;
             participation in this study and for at least 2 months after the last dose of the study&#xD;
             drug.&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity, intolerance, or allergy to opioids&#xD;
&#xD;
          -  Surgical procedures in the last 4 weeks or plans to undergo surgical procedures during&#xD;
             the study period&#xD;
&#xD;
          -  Untreated moderate to severe sleep apnea&#xD;
&#xD;
          -  Chronic migraines as the primary pain condition&#xD;
&#xD;
          -  Cancer related pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site - Saraland</name>
      <address>
        <city>Saraland</city>
        <state>Alabama</state>
        <zip>36571</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Tempe</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Little Rock</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Stamford</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Clearwater</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Fort Lauderdale</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Fort Myers</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32257</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Ormond Beach</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Plantation</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - West Palm Beach</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Blue Ridge</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Marietta</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Norcross</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Gurnee</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - West Des Moines</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Bossier</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Bay City</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Pinconning</name>
      <address>
        <city>Pinconning</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Biloxi</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Saint Louis 1</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Saint Louis 2</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Las Vegas 2</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Las Vegas 1</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Williamsville</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Greensboro</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Winston Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Beavercreek</name>
      <address>
        <city>Beavercreek</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Cincinnati 1</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Cincinnati 2</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Duncansville</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Jenkintown</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Dakota Dunes</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Rapid City</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Arlington</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Killeen</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Salt Lake City</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - West Jordan</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Midlothian</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site - Kenosha</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://academic.oup.com/painmedicine/article/doi/10.1093/pm/pnz169/5540711</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Gudin J, Rauck R, Argoff C, Agaiby E, Gimbel J, Katz N, Doberstein SK, Tagliaferri M, Tagliaferri M, Potts J, Wild J, Lu L, Siddhanti S, Hale M, Markman J. Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS). Pain Med. 2020 Nov 7;21(7):1347-1356. doi: 10.1093/pm/pnz169.</citation>
    <PMID>31361019</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>June 22, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <disposition_first_submitted>March 2, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 2, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 6, 2018</disposition_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02367820/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02367820/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject screened 14 April 2015. Last subject out: 24 January 2018. The study was conducted at 55 medical/research centers in the United States.</recruitment_details>
      <pre_assignment_details>The titration phase of the study was designed to titrate patients to a dose of NKTR-181 that provided adequate analgesia and acceptable side effects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NKTR-181</title>
          <description>NKTR-181 tablets at 100-600 mg orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="638"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="236"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set is defined as all enrolled subjects who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Rollover NKTR-181</title>
          <description>Subjects administered NKTR-181 in preceding phase 3 efficacy/safety study</description>
        </group>
        <group group_id="B2">
          <title>Rollover PBO</title>
          <description>Subjects administered placebo in preceding phase 3 efficacy/safety study</description>
        </group>
        <group group_id="B3">
          <title>De Novo Naive</title>
          <description>Newly enrolled opioid naïve subjects</description>
        </group>
        <group group_id="B4">
          <title>De Novo Opioid Experienced</title>
          <description>Newly enrolled opioid experienced subjects</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="214"/>
            <count group_id="B2" value="217"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="134"/>
            <count group_id="B5" value="638"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="12.01"/>
                    <measurement group_id="B2" value="51.4" spread="12.31"/>
                    <measurement group_id="B3" value="51.9" spread="10.44"/>
                    <measurement group_id="B4" value="55.6" spread="11.12"/>
                    <measurement group_id="B5" value="52.4" spread="11.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="431"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Adverse Events</title>
        <description>Count of subjects reporting treatment emergent adverse events</description>
        <time_frame>Screening baseline through end of study, an average of 57 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rollover NKTR-181</title>
            <description>Subjects administered NKTR-181 in preceding phase 3 efficacy/safety study</description>
          </group>
          <group group_id="O2">
            <title>Rollover PBO</title>
            <description>Subjects administered placebo in preceding phase 3 efficacy/safety study</description>
          </group>
          <group group_id="O3">
            <title>De Novo Opioid Experienced</title>
            <description>Newly enrolled opioid experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>De Novo Naive</title>
            <description>Newly enrolled opioid naïve subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events</title>
          <description>Count of subjects reporting treatment emergent adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Pain Inventory (BPI) Pain Intensity Item to Week 52</title>
        <description>A self-reported scale measuring severity of pain on function. The mean of the 4 intensity items (3-6) is calculated and used as a measure of pain severity. If there were missing items when the pain severity score was calculated, the mean of the completed items in one dimension (dimensions include pain severity and pain interference) were imputed to substitute the missing item, provided that more than 50% of the items in one dimension were completed (Halling, 1999). The range of pain intensity and interference for each question is from 0 to 10. The range of possible scores is from 0 to 70. Higher score indicates relatively worse pain severity and greater interference that pain causes in day to day activities.</description>
        <time_frame>Baseline, monthly change from baseline till the end of study</time_frame>
        <population>Safety Analysis Set is defined as all enrolled subjects who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Rollover NKTR-181</title>
            <description>Subjects administered NKTR-181 in preceding phase 3 efficacy/safety study</description>
          </group>
          <group group_id="O2">
            <title>Rollover PBO</title>
            <description>Subjects administered placebo in preceding phase 3 efficacy/safety study</description>
          </group>
          <group group_id="O3">
            <title>De Novo Opioid Experienced</title>
            <description>Newly enrolled opioid experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>De Novo Naive</title>
            <description>Newly enrolled opioid naïve subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory (BPI) Pain Intensity Item to Week 52</title>
          <description>A self-reported scale measuring severity of pain on function. The mean of the 4 intensity items (3-6) is calculated and used as a measure of pain severity. If there were missing items when the pain severity score was calculated, the mean of the completed items in one dimension (dimensions include pain severity and pain interference) were imputed to substitute the missing item, provided that more than 50% of the items in one dimension were completed (Halling, 1999). The range of pain intensity and interference for each question is from 0 to 10. The range of possible scores is from 0 to 70. Higher score indicates relatively worse pain severity and greater interference that pain causes in day to day activities.</description>
          <population>Safety Analysis Set is defined as all enrolled subjects who received at least 1 dose of study drug.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="129"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Intensity: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="188"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="1.968"/>
                    <measurement group_id="O2" value="4.11" spread="2.112"/>
                    <measurement group_id="O3" value="5.91" spread="1.749"/>
                    <measurement group_id="O4" value="6.18" spread="1.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="177"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="2.109"/>
                    <measurement group_id="O2" value="-1.71" spread="2.212"/>
                    <measurement group_id="O3" value="-2.19" spread="2.009"/>
                    <measurement group_id="O4" value="-2.66" spread="1.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="168"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="2.233"/>
                    <measurement group_id="O2" value="-1.40" spread="2.314"/>
                    <measurement group_id="O3" value="-2.26" spread="2.134"/>
                    <measurement group_id="O4" value="-2.26" spread="2.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="161"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="2.037"/>
                    <measurement group_id="O2" value="-1.58" spread="2.172"/>
                    <measurement group_id="O3" value="-2.01" spread="2.000"/>
                    <measurement group_id="O4" value="-2.49" spread="1.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="2.142"/>
                    <measurement group_id="O2" value="-1.48" spread="2.278"/>
                    <measurement group_id="O3" value="-2.06" spread="1.932"/>
                    <measurement group_id="O4" value="-2.38" spread="2.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="2.269"/>
                    <measurement group_id="O2" value="-1.44" spread="2.267"/>
                    <measurement group_id="O3" value="-2.04" spread="1.933"/>
                    <measurement group_id="O4" value="-2.58" spread="1.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 150</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="2.116"/>
                    <measurement group_id="O2" value="-1.54" spread="2.319"/>
                    <measurement group_id="O3" value="-2.09" spread="2.016"/>
                    <measurement group_id="O4" value="-2.44" spread="2.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="2.103"/>
                    <measurement group_id="O2" value="-1.49" spread="2.425"/>
                    <measurement group_id="O3" value="-1.87" spread="2.053"/>
                    <measurement group_id="O4" value="-2.80" spread="2.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="2.131"/>
                    <measurement group_id="O2" value="-1.58" spread="2.220"/>
                    <measurement group_id="O3" value="-2.06" spread="1.944"/>
                    <measurement group_id="O4" value="-3.01" spread="2.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="1.837"/>
                    <measurement group_id="O2" value="-1.82" spread="2.190"/>
                    <measurement group_id="O3" value="-2.21" spread="1.908"/>
                    <measurement group_id="O4" value="-2.84" spread="2.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="2.154"/>
                    <measurement group_id="O2" value="-1.62" spread="2.366"/>
                    <measurement group_id="O3" value="-1.83" spread="1.915"/>
                    <measurement group_id="O4" value="-2.65" spread="1.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 300</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="2.149"/>
                    <measurement group_id="O2" value="-1.48" spread="2.303"/>
                    <measurement group_id="O3" value="-2.08" spread="2.144"/>
                    <measurement group_id="O4" value="-2.31" spread="2.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Intensity: Change from Baseline to Day 364</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="2.175"/>
                    <measurement group_id="O2" value="-1.31" spread="2.520"/>
                    <measurement group_id="O3" value="-1.20" spread="2.102"/>
                    <measurement group_id="O4" value="-2.15" spread="2.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Pain Inventory (BPI) Pain Interference Item to Week 52</title>
        <description>A self-reported scale measuring interference of pain on function. The mean of the 7 interference items was calculated and used as a measure of Pain interference. If there were missing items when the pain interference score was calculated, the mean of the completed items in one dimension (dimensions include pain severity and pain interference) were imputed to substitute the missing item, provided that more than 50% of the items in one dimension were completed (Halling, 1999). The range of pain interference is from 0 to 10. Higher score indicates relatively worse pain problem.</description>
        <time_frame>Baseline, monthly change from baseline till the end of study</time_frame>
        <population>Safety Analysis Set is defined as all enrolled subjects who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Rollover NKTR-181</title>
            <description>Subjects administered NKTR-181 in preceding phase 3 efficacy/safety study</description>
          </group>
          <group group_id="O2">
            <title>Rollover PBO</title>
            <description>Subjects administered placebo in preceding phase 3 efficacy/safety study</description>
          </group>
          <group group_id="O3">
            <title>De Novo Opioid Experienced</title>
            <description>Newly enrolled opioid experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>De Novo Naive</title>
            <description>Newly enrolled opioid naïve subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory (BPI) Pain Interference Item to Week 52</title>
          <description>A self-reported scale measuring interference of pain on function. The mean of the 7 interference items was calculated and used as a measure of Pain interference. If there were missing items when the pain interference score was calculated, the mean of the completed items in one dimension (dimensions include pain severity and pain interference) were imputed to substitute the missing item, provided that more than 50% of the items in one dimension were completed (Halling, 1999). The range of pain interference is from 0 to 10. Higher score indicates relatively worse pain problem.</description>
          <population>Safety Analysis Set is defined as all enrolled subjects who received at least 1 dose of study drug.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="129"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Interference: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="188"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="2.205"/>
                    <measurement group_id="O2" value="3.25" spread="2.281"/>
                    <measurement group_id="O3" value="5.41" spread="2.298"/>
                    <measurement group_id="O4" value="5.44" spread="1.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="177"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="2.301"/>
                    <measurement group_id="O2" value="-1.52" spread="2.163"/>
                    <measurement group_id="O3" value="-2.34" spread="2.175"/>
                    <measurement group_id="O4" value="-2.71" spread="2.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="168"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="2.070"/>
                    <measurement group_id="O2" value="-1.29" spread="2.340"/>
                    <measurement group_id="O3" value="-2.51" spread="2.583"/>
                    <measurement group_id="O4" value="-2.17" spread="2.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="161"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="2.070"/>
                    <measurement group_id="O2" value="-1.32" spread="2.104"/>
                    <measurement group_id="O3" value="-2.18" spread="2.350"/>
                    <measurement group_id="O4" value="-2.38" spread="2.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="2.344"/>
                    <measurement group_id="O2" value="-1.34" spread="2.222"/>
                    <measurement group_id="O3" value="-2.15" spread="2.447"/>
                    <measurement group_id="O4" value="-2.11" spread="2.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="2.389"/>
                    <measurement group_id="O2" value="-1.36" spread="2.309"/>
                    <measurement group_id="O3" value="-2.33" spread="2.299"/>
                    <measurement group_id="O4" value="-2.48" spread="2.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 150</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="2.329"/>
                    <measurement group_id="O2" value="-1.22" spread="2.500"/>
                    <measurement group_id="O3" value="-2.26" spread="2.372"/>
                    <measurement group_id="O4" value="-2.16" spread="2.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="2.247"/>
                    <measurement group_id="O2" value="-1.33" spread="2.507"/>
                    <measurement group_id="O3" value="-2.09" spread="2.551"/>
                    <measurement group_id="O4" value="-2.27" spread="2.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="2.325"/>
                    <measurement group_id="O2" value="-1.29" spread="2.215"/>
                    <measurement group_id="O3" value="-2.43" spread="2.365"/>
                    <measurement group_id="O4" value="-2.38" spread="2.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="2.119"/>
                    <measurement group_id="O2" value="-1.55" spread="2.197"/>
                    <measurement group_id="O3" value="-2.49" spread="2.503"/>
                    <measurement group_id="O4" value="-2.27" spread="2.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="2.339"/>
                    <measurement group_id="O2" value="-1.37" spread="2.329"/>
                    <measurement group_id="O3" value="-2.02" spread="2.374"/>
                    <measurement group_id="O4" value="-2.01" spread="2.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 300</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="2.307"/>
                    <measurement group_id="O2" value="-1.38" spread="2.137"/>
                    <measurement group_id="O3" value="-2.07" spread="2.280"/>
                    <measurement group_id="O4" value="-1.94" spread="2.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Interference: Change from Baseline to Day 364</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="2.258"/>
                    <measurement group_id="O2" value="-1.14" spread="2.493"/>
                    <measurement group_id="O3" value="-1.33" spread="2.396"/>
                    <measurement group_id="O4" value="-2.08" spread="2.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported starting immediately after the subject provided written informed consent through the end of study, which was approximately 57-weeks in length for each subject.</time_frame>
      <desc>Adverse events were collected after the subject provided written informed consent through the end of study. Adverse event data were obtained via spontaneous reports or per direct questioning or observation during protocol-mandated study assessments. All ongoing AEs were followed until resolution or for 14 days after the subject's last visit, whichever came first. All SAEs were followed until resolution, stabilization of condition, return to baseline, or until follow-up was no longer possible.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rollover NKTR-181</title>
          <description>Subjects administered NKTR-181 in preceding phase 3 efficacy/safety study</description>
        </group>
        <group group_id="E2">
          <title>Rollover PBO</title>
          <description>Subjects administered placebo in preceding phase 3 efficacy/safety study</description>
        </group>
        <group group_id="E3">
          <title>De Novo Opioid Experienced</title>
          <description>Newly enrolled opioid experienced subjects</description>
        </group>
        <group group_id="E4">
          <title>De Novo Naive</title>
          <description>Newly enrolled opioid naïve subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hisoplasmosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="214"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="217"/>
                <counts group_id="E3" events="56" subjects_affected="56" subjects_at_risk="134"/>
                <counts group_id="E4" events="41" subjects_affected="41" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="214"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="217"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="134"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug withdrawal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="217"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="214"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="217"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="217"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="214"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="217"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="134"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="214"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="214"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a joint manuscript has not been submitted for publication within twelve (12) months of completion or termination of the study, the PI is free to publish separately, upon provision of any proposed publication or manuscript to the Sponsor at least sixty (60) days before it is submitted or otherwise disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs</name_or_title>
      <organization>Nektar Therapeutics</organization>
      <phone>855-482-8676</phone>
      <email>StudyInquiry@nektar.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

